Overview

A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.

Status:
Recruiting
Trial end date:
2022-06-13
Target enrollment:
Participant gender:
Summary
To perform a comparative evaluation on the pharmacokinetics and the safety after administration of "BR3003" and co-administration of "BR3003B" and "BR3003C" in healthy adults.
Phase:
Phase 1
Details
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Treatments:
Dapagliflozin
Pioglitazone